Diagnostic labs in emerging markets struggle to access reliable, affordable molecular tests that work in resource-constrained environments

Healthcare facilities in underserved regions across Africa and similar markets lack access to temperature-stable, affordable molecular diagnostic tests for critical diseases like TB, HIV, and hepatitis. Current solutions are either prohibitively expensive, require cold-chain infrastructure that doesn't exist, or are unavailable locally, forcing patients to go undiagnosed or travel long distances. This directly impacts disease detection rates and public health outcomes in regions with the highest disease burden.